Clinical effects of human macrophage inflammatory protein-1 alpha MIP-1 alpha (LD78) administration to humans: a phase I study in cancer patients and normal healthy volunteers with the genetically engineered variant, BB-10010.

2.50
Hdl Handle:
http://hdl.handle.net/10541/92030
Title:
Clinical effects of human macrophage inflammatory protein-1 alpha MIP-1 alpha (LD78) administration to humans: a phase I study in cancer patients and normal healthy volunteers with the genetically engineered variant, BB-10010.
Authors:
Marshall, E; Howell, Anthony ( 0000-0002-3879-5991 ) ; Powles, R; Hunter, M G; Edwards, M; Wood, L M; Czaplewski, L; Puttick, R; Warrington, S; Boyce, M; Testa, Nydia G; Dexter, T Michael; Lord, Brian I; Millar, A
Abstract:
BB-10010 is a genetically engineered variant of human macrophage inflammatory protein-1 alpha (hMIP-1 alpha) with improved pharmaceutical formulation properties. Although initially described as a pro-inflammatory cytokine, it is now recognised that hMIP-1 alpha has additional effects on haemopoietic stem cell cycling and on human immunodeficiency virus uptake by macrophages. In view of the potential clinical utility of the molecule, we have embarked on a clinical trials programme to evaluate the safety, tolerability and haematological effects of BB-10010. We now report the results of two phase I clinical studies in which 49 subjects (9 patients with advanced breast carcinoma and 40 normal healthy volunteers) received escalating doses of BB-10010, from 0.1 to 300 micrograms/kg using the subcutaneous (s.c.) or intravenous route (i.v.) of administration. Treatment was associated with a dose-related increase in monocyte count which peaked at 200% of steady-state levels and was preceded by an acute, short-lived, monocytopenia, 50-100% of baseline. no measurable effects were noted on other leucocyte subsets or on circulating progenitor cell numbers. In all cases, BB-10010 was extremely well tolerated with no significant toxicity observed at any dose level and a maximum tolerated dose was not defined. Pharmacokinetic analysis revealed that serum concentrations of BB-10010 were detectable using doses of > or = 10 micrograms/kg i.v. or > or = 30 micrograms/kg s.c., and that a single s.c. injection resulted in sustained plasma levels over a 24 h period. These preliminary studies have confirmed the safety and tolerability of BB-10010 using a dose range up to 300 micrograms/kg. Further clinical studies are ongoing to determine the biological effects and to investigate the potential myeloprotective properties using a variable dose range and schedule of BB-10010 in combination with cytotoxic chemotherapy.
Affiliation:
CRC Department of Medical Oncology, Christie Hospital, Manchester, U.K.
Citation:
Clinical effects of human macrophage inflammatory protein-1 alpha MIP-1 alpha (LD78) administration to humans: a phase I study in cancer patients and normal healthy volunteers with the genetically engineered variant, BB-10010. 1998, 34 (7):1023-9 Eur. J. Cancer
Journal:
European Journal of Cancer
Issue Date:
Jun-1998
URI:
http://hdl.handle.net/10541/92030
DOI:
10.1016/S0959-8049(97)10141-1
PubMed ID:
9849450
Type:
Article
Language:
en
ISSN:
0959-8049
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorMarshall, Een
dc.contributor.authorHowell, Anthonyen
dc.contributor.authorPowles, Ren
dc.contributor.authorHunter, M Gen
dc.contributor.authorEdwards, Men
dc.contributor.authorWood, L Men
dc.contributor.authorCzaplewski, Len
dc.contributor.authorPuttick, Ren
dc.contributor.authorWarrington, Sen
dc.contributor.authorBoyce, Men
dc.contributor.authorTesta, Nydia Gen
dc.contributor.authorDexter, T Michaelen
dc.contributor.authorLord, Brian Ien
dc.contributor.authorMillar, Aen
dc.date.accessioned2010-02-12T15:52:43Z-
dc.date.available2010-02-12T15:52:43Z-
dc.date.issued1998-06-
dc.identifier.citationClinical effects of human macrophage inflammatory protein-1 alpha MIP-1 alpha (LD78) administration to humans: a phase I study in cancer patients and normal healthy volunteers with the genetically engineered variant, BB-10010. 1998, 34 (7):1023-9 Eur. J. Canceren
dc.identifier.issn0959-8049-
dc.identifier.pmid9849450-
dc.identifier.doi10.1016/S0959-8049(97)10141-1-
dc.identifier.urihttp://hdl.handle.net/10541/92030-
dc.description.abstractBB-10010 is a genetically engineered variant of human macrophage inflammatory protein-1 alpha (hMIP-1 alpha) with improved pharmaceutical formulation properties. Although initially described as a pro-inflammatory cytokine, it is now recognised that hMIP-1 alpha has additional effects on haemopoietic stem cell cycling and on human immunodeficiency virus uptake by macrophages. In view of the potential clinical utility of the molecule, we have embarked on a clinical trials programme to evaluate the safety, tolerability and haematological effects of BB-10010. We now report the results of two phase I clinical studies in which 49 subjects (9 patients with advanced breast carcinoma and 40 normal healthy volunteers) received escalating doses of BB-10010, from 0.1 to 300 micrograms/kg using the subcutaneous (s.c.) or intravenous route (i.v.) of administration. Treatment was associated with a dose-related increase in monocyte count which peaked at 200% of steady-state levels and was preceded by an acute, short-lived, monocytopenia, 50-100% of baseline. no measurable effects were noted on other leucocyte subsets or on circulating progenitor cell numbers. In all cases, BB-10010 was extremely well tolerated with no significant toxicity observed at any dose level and a maximum tolerated dose was not defined. Pharmacokinetic analysis revealed that serum concentrations of BB-10010 were detectable using doses of > or = 10 micrograms/kg i.v. or > or = 30 micrograms/kg s.c., and that a single s.c. injection resulted in sustained plasma levels over a 24 h period. These preliminary studies have confirmed the safety and tolerability of BB-10010 using a dose range up to 300 micrograms/kg. Further clinical studies are ongoing to determine the biological effects and to investigate the potential myeloprotective properties using a variable dose range and schedule of BB-10010 in combination with cytotoxic chemotherapy.en
dc.language.isoenen
dc.subjectHaematopoietic Stem Cellsen
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshBreast Neoplasms-
dc.subject.meshChemokine CCL3-
dc.subject.meshChemokine CCL4-
dc.subject.meshDose-Response Relationship, Drug-
dc.subject.meshFemale-
dc.subject.meshHematopoietic Stem Cells-
dc.subject.meshHumans-
dc.subject.meshInfusions, Intravenous-
dc.subject.meshInjections-
dc.subject.meshLeukocyte Count-
dc.subject.meshLeukocytes-
dc.subject.meshMacrophage Inflammatory Proteins-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.titleClinical effects of human macrophage inflammatory protein-1 alpha MIP-1 alpha (LD78) administration to humans: a phase I study in cancer patients and normal healthy volunteers with the genetically engineered variant, BB-10010.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Medical Oncology, Christie Hospital, Manchester, U.K.en
dc.identifier.journalEuropean Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.